Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells

Claudia Dominici1, Nicolas Sgarioto2, Zhenbao Yu1, Laura Sesma-Sanz3, Jean-Yves Masson3, Stéphane Richard1* and Noël J.-M. Raynal2*

Abstract

Background: Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer-related death and represents a major health burden worldwide. Current therapies for NSCLC include chemotherapy, immunotherapy, and targeted molecular agents such as tyrosine kinase inhibitors and epigenetic drugs such as DNA methyltransferase inhibitors. However, survival rates remain low for patients with NSCLC, especially those with metastatic disease. A major cause for therapeutic failure is drug resistance, highlighting the need for novel therapies and combination strategies. Given that epigenetic modulators such as protein arginine methyltransferases (PRMTs) are frequently overexpressed in cancers, PRMT inhibitors are a promising class of cancer therapeutics. We screened a library of epigenetic and anticancer drugs to identify compounds that would synergize with MS023, a type I PRMT inhibitor, in decreasing the viability of methylthioadenosine phosphorylase (MTAP)-negative NSCLC cells.

Results: Among 181 compounds, we identified PARP inhibitors (PARPi) as having a strong synergistic interaction with type I PRMT inhibition. The combination of MS023 and the PARP inhibitor BMN-673 (Talazoparib) demonstrated strong synergistic interaction at low nanomolar concentrations in MTAP-negative NSCLC cell lines A549, SK-LU-1 and HCC4006. The re-introduction of MTAP decreased the sensitivity of the combination therapy in A549. The combination therapy resulted in elevated γ-H2AX foci indicating increased DNA damage causing decreased cell viability. Lastly, the combination therapy was effective in PARPi resistant ovarian cancer cells, suggesting that type I PRMT inhibitors could mitigate PARPi resistance, thus potentially having an important clinical impact for cancer treatment.

Conclusions: These findings identify a novel cancer drug combination therapy, which is more potent than the separate single-agent therapies. Thus, combining PARP inhibitors and type I PRMT inhibitors represents a new therapeutic opportunity for MTAP-negative NSCLC and certain cancer cells resistant to PARP inhibitors.

Keywords: Type I PRMT inhibitors, PARP inhibitors, MTAP, Drug resistance, Synergy, Non-small cell lung cancer cells, DNA damage, And cytotoxic

Background

Lung cancer is the leading cause of cancer-related death worldwide and is highly taxing on health care systems [1]. The vast majority (about 85%) of lung cancer cases are of the non-small cell lung cancer (NSCLC) subtype [2]. Early-stage NSCLC is addressed with surgery, however later stages NSCLC present a challenge that is not adequately met with current therapeutics [3, 4]. Myriad
oncogenic pathways have been identified in patients with NSCLC with varying degrees of penetration, such as aberrations in receptor tyrosine kinase signalling, mTOR signalling, and components of the cell cycle [4, 5]. While deficiencies in these well-studied pathways create an opening for targeted molecular therapies, the complex etiology of NSCLC presents a challenge in developing a unified therapy that can be extended to a broad range of patients. Targeting the epigenetic regulation with small molecule inhibitors provides a promising avenue in the development of successful therapies. Indeed, inhibitors of epigenetic modulators are actively being pursued [6, 7]. Unfortunately, single-agent delivery of epigenetic inhibitors has been met with limited success due to high toxicity or impermanent effects [8, 9]. Therefore, delivering combinations of synergetic epigenetic inhibitors at lower doses represents a suitable alternative. In fact, the success observed with targeting DNA methyltransferases (DNMTs) in combination with histone deacetylases (HDACs) in NSCLC provides a rationale for uncovering other combinations of epigenetic modifiers, which can be developed into effective therapies [10, 11].

Arginine methylation is an abundant post-translational modification identified in many proteins including histones, RNA-binding proteins, transcription factors and their coregulators, and DNA damage repair proteins [12]. Arginine methylation is mediated by a family of nine protein arginine methyltransferases (PRMTs) [13]. PRMTs transfer methyl groups from S-adenosylmethionine (SAM) to the guanidino nitrogens of arginine, generating methylated arginines and S-adenosylhomocysteine (SAH) as a by-product. PRMTs are divided into three subtypes [13]: type I catalyzes the formation of monomethylarginine (MMA) before a dimethylation reaction to produce asymmetric dimethylarginine (aDMA). PRMT1 is the type I enzyme responsible for the majority of aDMA. Type II enzymes also generate MMA as an intermediate for the production of symmetric dimethylarginine (sDMA), with PRMT5 being the major enzyme generating this modification. PRMT7 is only known type III enzyme only able to generate MMA [14]. The early discovery of a transcriptional co-activator function of PRMT1 and PRMT4 (CARM1) linked arginine methylation to the field of epigenetics [15, 16]. In addition, arginine methylation is known to be linked to double-strand DNA break (DSB) repair through methylating the DNA damage proteins and affecting cell cycle checkpoints [17–20].

Overexpression of PRMTs resulting in altered methyllarginine patterns is a common feature of cancer cells [21], and therefore PRMTs may serve as key therapeutic targets for intervention [12]. Promising small-molecule inhibitors exist for many PRMTs [22–26] and are in clinical trials. Notably, the type I PRMT inhibitor GSK3368715 is in phase I clinical trials for the treatment of diffuse large B-cell lymphoma and solid tumors (clinicaltrials.gov identifier number: NCT03666988). Additionally, PRMT5 inhibitors JNJ-64619178 and GSK3326595 are currently in phase I clinical trials (ClinicalTrials.gov identifier numbers NCT03573310 and NCT03614728, respectively) for patients with advanced cancers.

Substrate scavenging exists between type I and II PRMTs, leading to a global increase in MMA and sDMA, when PRMT1 is deleted [27]. This interplay between type I and type II PRMTs has recently been shown to have therapeutic value for cancer treatment and thus, it is not surprising that PRMT1 is synthetic lethal to PRMT5 deletion [24, 28, 29]. Since PRMTs require SAM as a methyl donor, they are inextricably linked to methionine metabolism. The enzyme 5-methylthioadenosine phosphorylase (MTAP) is a key component of the methionine salvage pathway. Due to its genomic proximity to the tumor suppressor genes CDKN2A and CDKN2B, the MTAP gene is commonly co-deleted in human cancer. This genetic deletion is found in ~40% of NSCLC patients [30]. Interestingly, MTAP-deleted cancer cells accumulate the metabolite methylthioadenosine (MTA), which is a high-affinity inhibitor of PRMT5 activity [31–33]. MTAP-negative A549 cells have elevated levels of MTA, resulting in endogenous PRMT5 inhibition [31–33]. As a result, inhibition of PRMT1 with the recently developed inhibitor of type I PRMTs, MS023 [23] or GSK3368715, is inherently optimal at reducing cell viability of MTAP-negative cells such as A549 [24, 28, 29].

Herein, we aimed to identify compounds that synergized with MS023 and elevated its cytotoxicity in the A549 NSCLC cell line. A library of epigenetic and anti-cancer compounds was screened, and we measured viability in the presence or absence of MS023. We identified several poly(ADP)-ribose polymerase (PARP) inhibitors that had a strong synergistic interaction with type I PRMT inhibition in A549 cells. This synergistic effect was partially attenuated in A549 cells stably transfected with MTAP expressing lentiviral vectors. Furthermore, we show that MS023 and the PARP inhibitor BMN-673 (Talazoparib) also synergized in SK-LU-1 and HCC4006 NSCLC cell lines. The combination therapy produced a significant increase in the accumulation of γ-H2AX foci indicating increased DNA damage, which was responsible for decreased viability. Furthermore, we show that MS023 lessened the resistance to PARP inhibition in the PEO ovarian cancer cell line, indicating a degree of robustness to the synergy of BMN-673 and MS023 in cancer cells. Our data identify a new combination therapy using type
I PRMT (MS023) and PARP (BMN-673; Talazoparib) inhibitors to effectively promote cell death of NSCLC.

Results
Cell viability screen with epigenetic/anticancer library identifies compounds that synergize with the type I PRMT inhibitor, MS023
Since PRMT overexpression has been implicated in various human cancers and deficiency of PRMT activity can inhibit cancer cell proliferation and lead to cell death [21], we initiated a small molecule library screen to identify epigenetic/anticancer drugs, which can cause synthetic lethality in combination with MS023, an inhibitor of type I PRMTs [23]. The ChemSelleck Epigenetic compound library is composed of 181 compounds with epigenetic and anticancer activities that is divided into 6 main families; angiogenesis (2.2%), cell cycle (3.9%), cell signalling (10.5%), JAK/STAT (12.7%), DNA damage (17.1%), and epigenetics (53.6%). The cell line chosen for screening was A549, a human MTAP-negative NSCLC cell line (Fig. 1a).

We first performed multiple dose–response experiments after a 24 h MS023 exposure and measured dose-dependent cell viability inhibition. We selected 16.5 μM as the concentration of MS023 to be used for the screen, which resulted in a 23% decrease in A549 cell viability (Fig. 1b). For drug screening, A549 cells were pre-treated with 16.5 μM MS023 for 24 h, and then exposed for an additional 24 h to the drug library at 10 μM. Cell viability was measured by flow cytometry using Viacount reagent, which distinguishes between viable, pre-apoptotic and dead cells based on the differential permeability of DNA-binding dyes. For all screened compounds, the mean cell viability was 77.2±16.4% in monotherapy (Fig. 1c). Pre-treatment with MS023 (16.5 μM, 24 h) followed by epigenetic/anticancer compounds (10 μM, 24 h) produced a global and significant 25% reduction (p<0.001) in cell viability to 54.2 ±19.4%, indicating a general sensitization effect of MS023 (Fig. 1c). We then calculated a synergy index displaying quantitatively synergistic and antagonistic drug interactions with MS023 by normalizing cell viability of drug combination data to cell viability of each compound alone, allowing result comparison between each drug combination (Fig. 1d). We observed that 58 (42%), 13 (10%), and 5 (3%) compounds produced synergistic synthetic cell death by more than 10%, 55%, and 75%, respectively. Antagonist interactions by more than 10 and 40%, were produced by 47 (30%) and 8 (4%) compounds, respectively (Fig. 1d). All drug screening data are shown in Additional file 1: Table 1. Confirmation experiments of 40 compounds (20 most active and 20 less active compounds) showed a validation rate of 70% (28/40; Additional file 1: Figure S1 and Table 2). These experiments indicate that MTAP-deficient A549 NSCLC cells are sensitized to epigenetic/anticancer drugs following type I PRMT inhibitor pre-treatment.

To identify pharmacological effects from groups of drugs with similar targets, we evaluated the synergy index by regrouping drugs based on target pathways (Fig. 2a), or molecular targets (Fig. 2b). Pie charts are showing the percentage of drugs among each target pathways and molecular targets (Fig. 2a, b). Within each target pathway or molecular target sub-groups, we calculated an enrichment score per class by normalizing the effect of each sub-group to the number of compounds per category. Thus, the enrichment score takes into account the percentage of synergy of each compound and its own weight in its sub-group. An enrichment score above 1 suggests a category that synergizes with MS023. When classified by target pathways, mean synergy index per class showed that compounds belonging to DNA damage pathway (enrichment score = 1.68) were the most synergistic with MS023 followed by JAK/STAT (enrichment score = 1.10). In contrast, epigenetics (enrichment score = 0.96), cell signaling (enrichment score = 0.74), cell cycle (enrichment score = 0.51), and angiogenesis (enrichment score = −1.12) drug classes had low enrichment scores (<1) and low to antagonistic synergistic index (Fig. 2a).

The two most enriched target pathways were DNA damage and JAK/STAT. When grouping based on molecular targets, compounds targeting DNA/RNA synthesis had the highest mean synergy index (enrichment score = 1.85) followed by PARP inhibitors (PARPi, enrichment score = 1.32; Fig. 2b). Interestingly, approved PARPi (Veliparib, Niraparib, and Olaparib) and PARPi in development (Iniparib, PJ34 HCl, and AZD2461) showed synergistic interactions with MS023, without causing cytotoxicity in monotherapy, suggesting a potentiation effect (Compounds that potentiate the effect of MS023 are found on the left-hand side of the graph, Fig. 2c).

Overall, our screen in the MTAP-negative A549 NSCLC cell line showed that PARPi exhibited a high synergistic interaction with a type I PRMT inhibitor, which may be easily combined in a clinical setting to increase therapeutic efficacy (Fig. 2a–c). Observing enrichment in this drug class prompted further investigation into the synergistic potential between PARPi and the type I PRMT inhibitor MS023.

Combination of MS023 with low concentrations of the PARP inhibitor BMN-673 (Talazoparib) results in synthetic lethality of A549 NSCLC cells
To confirm the activity of PARPi identified in our screens, we performed MTT-based cell viability assays (Fig. 3a). We used BMN-673 (Talazoparib), one of the recently approved PARPi, which displays high potency by

...
trapping PARP to DNA lesions [34, 35]. We used lower doses of MS023 while increasing treatment duration to 7 days as previously reported to significantly impact A549 cell viability [29]. We found that even at very low concentrations of BMN-673 (0.3 nM), the combination of the two inhibitors significantly killed more than 80% of the cells (Fig. 3b). We calculated the synergy score using the Bliss Synergy method and found that BMN-673 combined with MS023 produced a synergistic effect on cell death (Fig. 3c). These results demonstrate a significant synergistic effect at very low concentrations of PARP and type I PRMT inhibitors. Next, we asked whether the MTAP deficiency in A549 cells could play a role in the synergistic interaction between type I PRMT and PARP inhibitors. A549 cells were stably transfected with an MTAP expression vector and we generated two clones (A549 MTAP #1 and #2), which re-expressed the MTAP protein as visualized by immunoblotting (Fig. 4a). To
confirm the restored MTAP enzymatic activity, we measured symmetric arginine dimethylation (SDMA) levels by immunoblotting. MTAP re-expression in A549 clones #1 and #2 had an increase in SDMA levels, consistent with earlier findings that MTAP reduces MTA levels and de-represses PRMT5 inhibition (Fig. 4d) [31–33, 36].

First, we performed MTT assays in control (PLOC) and MTAP-expressing (clones #1, #2) A549 cells (Fig. 4c) to determine their sensitivity to MS023. The presence of MTAP reduced cell death induced by MS023 (PLOC-IC50: 4.4 µM; MTAP#1-IC50: 5.1 µM; MTAP#2-IC50: 13.4 µM). Then, A549 cells were treated with low dose MS023 (2 µM) and various doses of PARPi BMN-673 in the absence (PLOC) or in presence of MTAP (Fig. 4d). Interestingly, the presence of MTAP reduced cell death by at least 50% after exposure to the combination of MS023 and BMN-673 (at 25 and 50 nM), demonstrating that MTAP desensitizes A549 cell to the drug combination. To further explore the potential of the combination, we used two other MTAP-deficient NSCLC cell lines, SK-LU-1 and HC4006. Similarly to A549 cells, MTAP-expression conferred resistance to MS023-induced cell death in both cell lines as shown by increased IC50 values (Additional file 1: Figure S2A-D). Interestingly, the combination of MS023 and BMN-673 produced synergistic cell death in SK-LU-1 and HCC4006 (Additional file 1: Figure S2E-H). In contrast to A549 cells, MTAP expression in SK-LU-1 and HC4006 cells did not alter cell death induced by the drug combination, suggesting the involvement of other mechanisms (Additional file 1: Figure S2E, F). It is noteworthy that SK-LU-1 and HCC4006 cells (with or without MTAP) had slower doubling times than A549 cells suggesting that the impact of PARPi is likely to be dependent on the number of cell divisions. Additional experiments need to address these issues in the context of combination PRMT1 and PARPi.

Next we asked whether inhibitors of other types of PRMTs, such as PRMT5 (EPZ015666 and GSK591) could synergize with PARPi BMN-673. Cell death was measured in A549 cells using the Viacount reagent after treatment with MS023 (2 µM), EPZ015666 (2.5–5 µM), and GSK591 (2.5–5 µM) alone or in combination with BMN-673 (0.3–50 nM; Fig. 5a). Interestingly, the type I PRMT inhibitor (MS023) demonstrated superiority to induce cell death in combination with the lowest dose of PARPi (0.3 nM), as compared to PRMT5 inhibitors. However, higher doses of PARPi enhanced the activity of both PRMT5 inhibitors (producing synergistic Bliss synergy scores), as also observed by others [20], suggesting some redundancy between PRMT1 and PRMT5 pathways (Fig. 5b, c). Overall, the data support the rationale to combine PRMT inhibitors with PARPi to induce lung cancer cell death at low doses.

A549 cells treated with a combination of MS023 and BMN-673 accumulate γ-H2AX foci
PARP inhibitors are well-known for generating synthetic lethality in BRCA-mutant breast and ovarian cancer cells, which is largely attributed to a deficiency in homologous recombination (HR) [37–40]. Considering that both PRMTs and PARPs are functionally involved in the DNA damage response, we performed γ-H2AX foci analysis to monitor DNA damage in A549 cells. Treatment for 7 days with either MS023 (2 µM) or BMN-673 (50 nM) induced γ-H2AX foci formation, as observed by immunofluorescence (Fig. 6a). These observations suggest that the single drug treatments were able to induce a certain level of DNA damage on their own. The combination therapy using both inhibitors led to a significant increase in γ-H2AX foci, implying increased DNA damage being responsible for the reduced viability (Fig. 6a). More precisely, low concentrations of BMN-673 (1–50 nM) produced a significant increase in the percentage of cells (1 nM, 24.8%; 50 nM, 40.4%) with greater than five γ-H2AX (p<0.0001), as compared to untreated cells (3.9%; Fig. 6b). Low concentrations of MS023 (0.2–2 µM) produced similar effects (0.2 µM, 19.6%; 2.0 µM, 27.6%; Fig. 6b). The combination of BMN-673 (50 nM) and MS023 (2 µM) produced a significant increase in the percentage of cells (69.5%) with greater than five γ-H2AX foci (p<0.001; Fig. 6b). Overall, the data show that the drug combination of PARP and type I PRMT inhibitors
elevate cytotoxicity by augmenting DNA damage in MTAP-negative A549 cells.

PRMT inhibitors restore PARP inhibitor sensitivity
We asked whether the synergic relationship between MS023 and BMN-673 could be extended to PARPi-resistant cells. We used the ovarian cancer cell lines PEO1 and PEO4, which are derived from the same patient [41]. PEO1 cells are BRCA2-deficient and show sensitivity to PARPi, MS023 and their combination (Fig. 7a). PEO4 cells have a secondary BRCA2 mutation, which restores BRCA2 expression and are therefore resistant to BMN-673 alone (Fig. 7b). Interestingly, we observed a synergistic effect of the combination of MS023 and BMN-673 not only on the PEO1 cells, but also in the PEO4 BMN-673-resistant cells, as demonstrated by the high bliss score values in both cell lines (Fig. 7c, d). These results indicate that type I PRMT inhibition in combination with PARPi may be used to treat tumors that present resistance to PARPi through HR restoration (Fig. 7e).

Discussion
In the present manuscript, we performed a chemical screen to identify epigenetic and anticancer drugs that synergize with a type I PRMT inhibitor, MS023. Homozygous deletion of the MTAP gene is frequently (~40%) seen in lung cancer patients [30], and leads to elevated levels of MTA, a metabolite known to act as an endogenous inhibitor of PRMT5 activity [31–33]. As such, MTAP-deficient cancer cells are inherently sensitive to
inhibition of PRMT1 [24, 28, 29]. As resistance occurs frequently in NSCLCs, we aimed to identify additional compounds that could function in combination therapy with MS023 to significantly increase its cytotoxicity in the MTAP-negative A549 cell line. We identified several PARPi that had a strong synergy index with type I PRMT inhibition. We further examined the combination of MS023 and the PARP inhibitor BMN-673 (Talazoparib), and observed strong synergistic interaction at low nM concentrations in MTAP-negative A549, SK-LU-1 and HCC4006 NSCLC cells. The re-introduction of MTAP decreased the sensitivity of the combination therapy in A549 cells. Importantly, PARP inhibitor sensitive and resistant cells (PEO1, PEO4) were both sensitive to the combination therapy of MS023 and BMN-673. These data suggest that type I PRMT inhibitors may have a wide therapeutic window targeting certain NSCLC and ovarian cancers in combination with PARPi inhibitors.

PARPs are a family of enzymes with at least 18 members that catalyze the addition of poly(ADP-ribose) to various biological molecules. The most well-studied member of the PARP family, PARP1, plays an important role in DNA damage repair and is able to catalyze poly (ADP-ribose) chains [42, 43]. Inhibitors of PARP generate synthetic lethality in BRCA1- and BRCA2-mutant breast/ovarian cancer cells [37–40]. Four PARP inhibitors have been approved by regulatory agencies, including Olaparib and Rucaparib in BRCA-mutated ovarian cancer; Niraparib in epithelial ovarian, fallopian tube and primary peritoneal cancer; and Talazoparib in BRCA-mutated breast cancer [44, 45]. Importantly, several compounds are being pursued as promising combinatorial agents with PARPi in several types of cancers [46–49]. Defining additional inhibitors that will work in combination with PARPi is paramount since resistance to PARPi single agent can occur through increased drug efflux, reactivation of homologous recombination, restoration of replication fork stability, or loss of DNA double-strand break resection inhibition [50].

We now identify type I PRMT inhibitors as functioning to kill NSCLC. Type I PRMT inhibition or PRMT1 deficiency is known cause DNA damage with homologous recombination defects [18]. Thus, it is likely that MS023 creates HR defects similar to what is observed in BRCA-mutated cancers, thereby creating a vulnerability for PARPi. The combination of MS023 and PARP inhibitors can be used to ablate HR-proficient cancers. Indeed, PARP inhibitors have also been used in combination with other agents to treat HR-proficient cancers [44, 51–53].

At sites of DNA damage, negatively charged PARylated proteins including PARP1 itself may recruit positively charged RGG/RG motif-containing methylated proteins. Arginine methylation plays a key role in the DNA damage response (DDR), and is known to occur
at the RGG/RG motifs on several DDR proteins, including MRE11, 53BP1, and BRCA1 [21, 54–57]. Therefore, arginine methylation of these proteins may affect their interactions with chains of PAR. Collectively, the combination of lack of arginine methylation and PARylation leads to DNA repair defects, causing synthetic lethality in MTAP-negative NSCLC.
Conclusions
As with any chemotherapy, the potential cytotoxicity of PARPi either alone or in combination with other agents needs to be considered. Importantly, we show that low concentrations of BMN-673 PARPi (0.3 nM) were sufficient to kill lung cancer cells in combination with MS023.
As demonstrated in our present study, the PARP and PRMT combination may be useful for recombination (HR) repair-deficient and proficient cancers. Due to the redundancy of PRMT1 and PRMT5 pathways, we also demonstrated that PARPi were effective in combination with PRMT5 inhibitors. Indeed, PARPi have been shown to synergize with PRMT5 inhibitors [20]. In sum, our findings show that targeting PRMTs in combination with PARP inhibitors presents as a new therapy option for NSCLC cancers that are HR-proficient.

Materials and methods

Cell culture and generation of stable cell lines

Lung carcinoma cells A549 (ATCC CCL-185), SK-LU-1 (ATCC HTB57) and HCC4006 (ATCC CRL-2871) were cultured in F12K, DEMEM and RPMI-1640 (GE Healthcare Life Sciences, Canada) respectively, supplemented with 10% of FBS (Wisent, Canada), and maintained in a humidified incubator with 5% CO₂ at 37 °C. Cells were regularly checked for mycoplasma infection and kept at low passages. Cell lines re-expressing MTAP were generated by infecting the MTAP-deficient cell lines A549, SK-LU-1 and HCC4006 with human MTAP lentivirus (pLoc-MTAP). The MTAP-infected cells were treated with 3 μg/ml blasticidin and single clones were selected. MTAP expression was confirmed by Western blot using anti-MTAP antibody (Cell Signaling Technology, 4158). As a control, the cells were also infected with lentiviral empty vector (pLoc). The MTAP-infected cells and single clones were selected. Ovarian adenocarcinoma cells PEO1 and PEO4 were a kind gift from Scott H. Kaufmann (Mayo Clinic). Cells were cultured in OSE (Wisent, Canada) supplemented with 10% of FBS (Wisent, Canada), and maintained in a humidified incubator with 5% CO₂ at 37 °C. For combination survival assays, PEO1 and PEO4 cells were seeded at 3,000 cells/well in flat bottom black 96-well plates (Corning). One day after plating, cells were treated with the indicated concentrations of MS023 (Cayman Chemical) and/or BMN-673 (SelleckChem, S7048), or an equivalent concentration of vehicle (DMSO, Sigma-Aldrich). The next day, 181 drugs from the SelleckChem epigenetic library (Epigenetics Compound Library (96-well)-Z203065-100 μl-L1900) were added at 10 μM for 24 h. Each plate contained controls to assess the individual effects of DMSO and MS023 on cells. On the third day, cell viability was measured using Viacount (Luminex, 4000-0040) on Guava flow cytometer (Millipore) as follows. Media was collected for each well and kept aside for later, cells were rinsed in 200 μl PBS without calcium (Wisent) and incubated with 0.25% trypsin (Gibco) for 5 min at 37 °C. Media of each well was added to stop trypsinization and mixed thoroughly with Integra 96-well automated pipettor. One control well (DMSO) was heat-killed to obtain a total cell death control. Viacount solution (25 μl) was added and mixed to each well, as suggested per manufacturer guidelines. After incubation (5 min at room temperature, in the dark), cell viability was analyzed on the Guava flow cytometer. The drug library was screened in monotherapy, as previously described. The Synergy Index (SI) is calculated as follows: SI = (Viability in monotherapy × MS023 Viability effect)/ Viability in combination. We also calculated a synergy/antagonism percentage value to associate a score to the combination as compared to monotherapy. The synergy/antagonism percentage is calculated as follows: 1 −(1/Synergy Index)*100.

Enrichment score was calculated to express relative effect of a drug class to other drug classes present in the library. Enrichment score is the ratio of its enrichment index and the global index of the whole screen. To calculate the enrichment index, we created a frequency table of each drug response per group. The matrix is composed
of 21 bins from -100 to 100, with a step of 10. Then, we calculate the representative percentage (weight) of each bin per group (bin weight = bin frequency / total number of compounds per group), to create 21 pairs per group. Finally, we sum up for each group the product of each (bin, weight) pairs. The global index is calculated the same way. The enrichment score corresponds to the ratio of each group index divided by the global index: a score > 1 shows an enrichment whereas a score < 1 shows the opposite.

**MTT assay**

A549, SK-LU-1 and HCC4006 stable cells infected with MTAP or empty lentiviral vectors were treated as described above with different dosages of inhibitors for 7 days. For treatment, the type I PRMT inhibitor MS023 was dissolved in DMSO to prepare a 3 mM stock solution, and cells were treated with a final concentration of 0.2–2 µM as indicated. The PARP1/2 inhibitor BMN-673 (SelleckChem, S7048) was also dissolved in DMSO to prepare a 3 mM stock solution, and cells were treated with a final concentration of 0.3–50 nM as indicated. For treatment, cells were seeded on day zero and inhibitors or DMSO were replenished every 48 h. Cell viability was assessed using the MTT assay kit (Abcam, ab211091) according to manufacturer’s instructions. Briefly, cells were grown in a 96-well plate and each treatment group was repeated in triplicate. On the 7th day, cells were carefully aspirated and 100 µl of 1X MTT reagent was added to each well, and the plate was incubated for 3 h at 37 °C. Following incubation, 150 µl of MTT solvent was added to each well and incubated at room temperature on an orbital shaker for 15 min prior to reading absorbance at OD = 590 nm. To normalize absorbance values, each value for the inhibitor-treated wells was divided by the absorbance of the DMSO-treated wells. Absorbance values are proportional to cell number, so percent cell death was determined by subtracting the normalized values from 1. An evaluation of the drug combination effect was carried out using the Bliss Independence dose–response calculation [58, 59].

**Immunofluorescence**

A549 cells were cultured on glass coverslips under the cell culture treatment conditions described above for the MTT assay. On day 7, coverslips were transferred to a solution of 4% paraformaldehyde in PBS and fixed for 15 min at room temperature. Cells were then permeabilized with 0.2% Triton X-100, 0.125 M glycine in PBS for 12 min at room temperature. Blocking followed for 1 h at room temperature with 2% BSA, 2% horse serum and 0.1% Triton X-100 in PBS. γ-H2AX foci were detected using anti-gamma H2A.X (Abcam, ab11174) diluted 1:1000 in blocking buffer and incubated at 4 °C for 16 h. Cells were washed three times with PBS for 10 min and incubated with secondary antibody (AlexaFluor anti-mouse 488 nm) diluted 1:400 for 45 min in the dark at room temperature. Cells were then washed three times for 10 min with PBS. Finally, coverslips were inverted and mounted onto a microscope slide with Immu-Mount (Fisher Scientific) and DAPI for counterstain. Slides were imaged on a Zeiss Axio Imager M1 microscope (Carl Zeiss, Thornwood NY), and resulting images were analyzed using Zeiss’ ZEN Digital imaging suite software. A minimum of 200 cells per treatment condition were imaged, and cells with >5 γH2AX foci were quantified and divided by total number of cells as determined by DAPI counterstain.

**Statistical analyses**

Statistical significance was determined using GraphPad Prism version 6.0 software to perform unpaired t tests, where p values less than 0.05 were accepted as significant.

**Abbreviations**

aDM: Asymmetric dimethylarginine; DNMT: DNA methyltransferase; DSB: Double-strand break; HDAC: Histone deacetylase; MMA: Monomethylarginine; MTA: Methylthioadenosine; MTAP: Methylthioadenosine phosphorylase; NSCLC: Non-small cell lung carcinoma; PARP: Poly(ADP)-ribose polymerase; PARPi: PARP inhibitor; PRMT: Protein arginine methyltransferase; SAH: S-adenosylhomocysteine; SAM: S-adenosylmethionine; sDMA: Symmetric dimethylarginine.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13148-021-01037-1.

**Additional file 1. Figure S1. Validation of the drug screen.** Graphic showing original data from the screen (plain circle) highest (20) and lowest (20) hits. Results from the validation are labelled with (+) if validation was confirmed or (−) if validation failed. Pie chart summarizes result of validation process; 28 of 40 compounds matched the primary output, leading to a validation rate for the screen of 70%. Figure S2. MS023 and BMN-673 synergy dependency on MTAP in NSCLC cell lines. A) Immunoblotting of SK-LU-1 and HCC4006 cell lines infected with the empty lentivector (pLoc) or pLoc-MTAP. Clones #1 and #2 show the re-expression of MTAP using anti-MTAP antibodies. Antibodies against β-actin were used to show equivalent loading. The molecular mass markers are shown in kDa. B) Same as panel A except the cellular lysates were immunoblotted with anti-SDMA and β-actin antibodies as indicated. (C-D) Cell death curves as determined by MTT assay of the SK-LU-1 and HCC4006 clones treated with a range of MS023 concentrations. Dotted vertical lines represent IC_{50} values for each cell line (SK-LU-1: n = 5; HCC4006: n = 4). Stars (*: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001; two-way ANOVA). E-F) Cell death curves as determined by MTT assay of the SK-LU-1 and HCC4006 clones treated with a range of BMN-673 in combination 10 µM MS023 (SK-LU-1, n = 4) or 0.2 µM MS023 (HCC4006, n = 6). G-H) Bliss synergy scores calculated for BMN-673 and MS023 combination treatment in SK-LU-1 and HCC4006 cells, respectively. Table 1. Drug screening results. Synergy indexes are shown for the 181 compounds treated in combination with MS023 in A549 cells. Table 2. Drug validation results. Synergy indexes are shown for the 40 compounds (20 highest and 20 lowest hits).
Acknowledgements

We thank Marielle Huot for generating the Bliss graphical representation.

Authors’ contributions

CD and ZY performed MTT assays and immunochemistry experiments, NS performed the drug screening and drug screening analysis. LSS performed the ovarian cell lines experiment. CD, LSS, ZY, NS, JYM, SR, and NJ-MR designed experiments, analyzed data and wrote the manuscript. All authors read and approved the final manuscript.

Funding

This work was funded by Canadian Institute of Health Research Grants: FDN-154303 to SR, NRF-173588 to NJ-MR, and FDN-388879 to JYM and by Charles-Bruneau Foundation. CD holds a Fonds de recherche du Québec en Santé studentship award. JYM is a Tier I Canada Research Chair in DNA repair and Cancer Therapeutics. NJ-MR holds a Junior 2 Research Scholar Award from the Fonds de recherche du Québec en Santé.

Availability of data and materials

All data generated or analysed during this study are included in this published article and its supplementary information files.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Segal Cancer Center, Lady Davis Institute for Medical Research and Gerald Bronfman Department of Oncology and Departments of Biochemistry, Human Genetics and Medicine, McGill University, Montréal, QC H3T 1E2, Canada. 2 Département de Pharmacologie et Physiologie, Université de Montréal, and Research Centre of the Sainte-Justine University Hospital, Montréal, QC H3T 1C5, Canada. 3 Genome Stability Laboratory, CHU de Québec Research Center, Oncology Division, Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, 9 McMahon, Québec, QC G1R 3S3, Canada.

Received: 17 July 2020   Accepted: 22 February 2021

Published online: 10 March 2021

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94.
3. Vansteenkiste J, Cninò L, Dooms C, Doulliard JY, Faivre-Finn C, Lim E, et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014;25(8):1462–74.
4. Herbst RS, Morgenstern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–54.
5. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455(7216):1069–75.
6. Schiffmann I, Greve G, Jung M, Lubbert M. Epigenetic therapy approaches in non-small cell lung cancer: update and perspectives. Epigenetics. 2016;11(12):858–70.
7. Shi YX, Sheng DQ, Cheng L, Song XY. Current landscape of epigenetics in lung cancer: focus on the mechanism and application. J Oncol. 2019;2019:8107318.
8. Vansteenkiste J, Van Cutsem E, Dumez H, Chen C, Rickers JL, Randolph SS, et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs. 2008;26(5):483–8.
9. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011;1(7):589–607.
10. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21(1):103–7.
11. Huang Y, Vasiliatos SN, Bosc L, Shaw PG, Davidson NE. Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. Breast Cancer Res Treat. 2012;131(3):777–89.
12. Guccione E, Richard S. The regulation, functions and clinical relevance of arginine methylation. Nat Rev Mol Cell Biol. 2019;20(10):642–57.
13. Bedford MT, Clarke SG. Protein arginine methylation in mammals: who, what, and why. Mol Cell. 2009;33(1):1–13.
14. Feng Y, Maity R, Whitelegg JP, Hadjikyriacou A, Li Z, Zuntra-Lopez C, et al. Mammalian protein arginine methyltransferase 7 (PRMT7) specifically targets RXR sites in lysine- and arginine-rich regions. J Biol Chem. 2013;288:37010–25.
15. Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT, et al. Regulation of transcription by a protein methyltransferase. Science (New York, NY). 1999;284(5423):2174–7.
16. Wang H, Huang Z-Q, Xia L, Feng Q, Erdjument-Bromage H, Strahl BD, et al. Methylation of histone H4 at arginine 3 facilitates transcriptional activation by nuclear hormone receptor. Science (New York, NY). 2001;293:853–7.
17. Boixvert F-M, Déuy U, Masson J-Y, Richard S. Arginine methylation of MRE11 by PRMT1 is required for DNA damage checkpoint control. Genes Dev. 2005;19(6):671–6.
18. Yu Z, Chen T, Hebert J, Li E, Richard S. A mouse PRMT1 null allele defines an essential role for arginine methylation in genome maintenance and cell proliferation. Mol Cell Biol. 2009;29(11):2982–96.
19. Clarke TL, Sanchez-Ballon MP, Chiang K, Reynolds JJ, Hennero-Ruiz J, Bandeiras TM, et al. PRMT5-dependent methylation of the Tip60 coactivator RUVBL1 is a key regulator of homologous recombination. Mol Cell. 2017;65:900–16.
20. Hamard P-J, Santiago GE, Liu F, Karl DL, Martinez C, Man N, et al. PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes. Cell Rep. 2018;24(10):2643–57.
21. Yang JH, Chiu HY, Fu SL, Shih IY, Weng TH, Lin WL, et al. Arginine methylation of hnRNPK negatively modulates apoptosis upon DNA damage through local regulation of phosphorylation. Nucleic Acids Res. 2014;42(15):9908–24.
22. Chan-Penebre E, Kuplast KG, Majer CR, Boriaak-Sjodin PA, Wigle TJ, Johnston LD, et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015;11:1422–7.
23. Eram MS, Shen Y, Szewczyk M, Wu H, Senisterra G, Li F, et al. A potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases. ACS Chem Biol. 2016;11(3):772–81.
24. Fedorov A, Rajapakur SR, O'Brien S, Gerhart SV, Mitchell LH, Adams ND, et al. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. Cancer Cell. 2019;36:100–14.
25. Nakayama K, Szewczyk MM, Dela Sena C, Wu H, Dong A, Zeng H, et al. TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma. Oncotarget. 2018;9(26):18480–93.
26. Szewczyk MM, Ishikawa Y, Orgán S, Sakai N, Li F, Halaban R, et al. Pharmacological inhibition of PRMT7 links arginine monomethylation to the cellular stress response. Nat Commun. 2020;11(1):2396.
27. Dhar S, Vemulapalli V, Patananan AN, Huang GL, Di Lorenzo A, Richard S, et al. Loss of the major type I arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs. Sci Rep. 2013;3:1311.
28. Fong JY, et al. Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation. Cancer Cell. 2019;36:194–209.
29. Gao G, Zhang L, Villarreal OD, He W, Su D, Bedford E, et al. PRMT1 loss sensitizes cells to PRMT5 inhibition. Nucleic Acids Res. 2019;47(10):5038–48.
30. Schmid M, Malicki D, Nobori T, Rosenbach MD, Campbell K, Carson DA, et al. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). Oncogene. 1998;17(20):2669–75.
31. Kryukov GV, Wilson FH, Rodriguez LE, Donawho CK, DiGammarno EL, et al. Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol Cancer Res. 2015;13(11):1465–77.
32. Fedoriw A, Rajapurkar SR, O'Brien S, Clasquin MF, Mandley E, Kunii K, et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis. Cell Rep. 2016;15(3):574–87.
33. Mavráki KJ, McDonald ER 3rd, Schlabach MR, Hsu YC, Hoffman GR, de Weck A, et al. Disordered methionine metabolism in MATP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science. 2016;351(6278):1208–13.
34. Hoy SM. Talazoparib: first global approval. Drugs. 2018;78(18):1939–46.
35. Hopkins TA, Shi Y, Rodriguez LE, Solomon LR, Donawho CK, DiGammadno EL, et al. Methionine metabolism in MATP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science. 2016;351(6278):1208–13.
36. Farmer H, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.
37. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Sci Rev Oncol Hematol. 2010;18(2):W488–W93.
38. Liu Q, Yin X, Languino LR, Altieri DC. Evaluation of drug combination synergism of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study. Clin Cancer Res. 2020;26:4268–79.
39. Pulliam N, Fanger F, Fosse AR, Tang J, Adevuyi A, Keer H, et al. An Effective epigenetic-PARP inhibitor combination therapy for breast and ovarian cancers independent of BRCA mutations. Clin Cancer Res. 2018;24(13):3163–75.
40. Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, et al. Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer, a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019;20(4):570–80.
41. Ronato DA, Mersaouli SY, Busatto FF, Affar EB, Richard S, Masson JY. Limiting the DNA double-strand break resesctosome for genome protection. Trends Biochem Sci. 2020;45(9):779–93.
42. Amin O, Beauchamp MC, Nader PA, Laskov I, Iqbal S, Philip CA, et al. Suppression of homologous recombination by insulin-like growth factor-I inhibition sensitizes cancer cells to PARP inhibitors. BMC Cancer. 2015;15:817.
43. Ibrahim YH, García-Garcia C, Serra Y, He L, Torres-Lockhart K, Prat A, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2(11):1036–47.
44. Mo W, Liu Q, Lin CC, Dai H, Peng Y, Liang Y, et al. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer. Clin Cancer Res. 2016;22(7):1699–712.
45. Aycluar V, Richard S. The role of arginine methylation in the DNA damage response. DNA Repair. 2013;12(7):459–65.
46. Guendel I, Carpio L, Pedati C, Schwartz A, Teal C, Kashanchi F, et al. Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional cofactor function. PLoS ONE. 2010;5(6):e11379.
47. Gurunathan G, Yu Z, Coulombe Y, Masson JY, Richard S. Arginine methylation of hnRNPUL1 regulates interaction with NBS1 and recruitment to sites of DNA damage. Sci Rep. 2015;5:10475.
48. Vadhvis C, Chen R, Fraszczyk J, Yu Z, Bouali J, Rinder J, et al. Gfi1 facilitates efficient DNA repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1. Nat Commun. 2018;9(1):1418.
49. Janevski A, Giri AK, Attakooli T, SynergyFinder 2.0 visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48(W1):W488–W93.
50. Liu Q, Yin X, Languino LR, Altieri DC. Evaluation of drug combination effect using a Bliss independence dose-response surface model. Stat Biopharm Res. 2018;10(2):112–22.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.